What should the Summary highlight according to the guidelines?

• A. The site visit calendar
• B. The sponsor's corporate structure
• C. Significant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, metabolic, and clinical information relevant to development
• D. The raw data by patient

Answer: (C)

The main idea is that the Summary should bring forward the significant information about the investigational product that informs its development and risk assessment. It should cover physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, metabolic, and clinical data that are relevant to development, presented in a concise, aggregated form so investigators and sponsors can quickly grasp how the product behaves, its potential safety concerns, and the rationale for its continued development. This helps frame the risk/benefit discussion and guides trial design.

Items like a site visit calendar or the sponsor’s corporate structure aren’t part of what the Summary should convey, and raw data by patient isn’t appropriate for the Summary either—the focus is on significant information across relevant domains in an aggregated, informative way.